CSN Login
Members Online: 16

Please let me know which of these studies you are interested in reading

hopeful and opt...
Posts: 1282
Joined: Apr 2009

click here to view this message online  

prostate<br />
cancer weekly header

Prostate Cancer

A discussion of the value and benefit of transrectal power Doppler sonography for detecting low-risk prostate cancers, "Beyond the Abstract," by J.-L. Sauvain, and E. Sauvain
Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease - Abstract
Racial differences in social support and coping among family caregivers of patients with prostate cancer - Abstract
Prostate cancer risk in rre-diabetic men: A matched cohort study - Abstract
High dose rate brachytherapy as monotherapy for localised prostate cancer: A hypofractionated two-implant approach in 351 consecutive patients - Abstract
Real-time contrast-enhanced transrectal US-guided prostate biopsy: Diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings - Abstract
Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population? - Abstract
Sentinel lymph node dissection in more than 1200 prostate cancer cases: Rate and prediction of lymph node involvement depending on preoperative tumor characteristics - Abstract
Application and clinical benefits of degarelix, a GnRH antagonist, in the treatment of advanced prostate cancer, "Beyond the Abstract," by Neal D. Shore, MD, FACS
Statement by NIH Director Francis Collins on U.S. Supreme Court ruling on gene patenting
Breaking News: Can someone else patent your genes? No, according to a closely watched ruling from the U.S. Supreme Court Thursday morning
ASCO 2013 - Poster: Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer
ASCO 2013 - Poster: A phase II multicenter study of the investigational single agent orteronel (TAK-700) in non-metastatic castration-resistant prostate cancer (nmCRPC [M0]) and rising prostate-specific antigen (PSA)
Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: Results from a randomized trial - Abstract
Sperm banking is of key importance in patients with prostate cancer - Abstract
Patients undergoing radical prostatectomy have a better survival than the background population - Abstract
Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer - Abstract
Classifying the reasons men consider to be important in prostate-specific antigen (PSA) testing decisions: Evaluating risks, lay beliefs, and informed decisions - Abstract
Plan of the day selection for online image-guided adaptive post-prostatectomy radiotherapy - Abstract
Current role of surgery for high risk prostate cancer - Abstract
Cost-benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer - Abstract
Platinum-based chemotherapy for variant castrate-resistant prostate cancer - Abstract
Functional and molecular imaging of localized and recurrent prostate cancer - Abstract
PSA screening and deaths from prostate cancer after diagnosis-A population based analysis - Abstract
Discussing uncertainty and risk in primary care: Recommendations of a multi-disciplinary panel regarding communication around prostate cancer screening - Abstract
Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer - Abstract
Pre-radiotherapy PSA level as a predictor for biochemical control in prostate cancer patients receiving radiotherapy after radical prostatectomy - Abstract
Assessment of antimicrobial prophylaxis to prevent perioperative infection in patients undergoing prostate brachytherapy: Multicenter cohort study - Abstract
Radiotherapy in the management of prostate cancer after radical prostatectomy - Abstract
Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes - Abstract
Prostate cancer detection by using digital rectal examination: Contemporary practice patterns in the United States - Abstract
Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy - Abstract
Management of high-risk prostate cancer: Radiation therapy and hormonal therapy - Abstract
Image-guided method for TLD-based in vivo rectal dose verification with endorectal balloon in proton therapy for prostate cancer - Abstract
Investigation of (90)Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I–II clinical study - Abstract
Bone turnover markers in patients with prostate carcinoma: Influence of sex steroids levels - Abstract
Anxiety status and its relationship with general health related quality of life among prostate cancer patients in two university hospitals in Kuala Lumpur, Malaysia - Abstract
Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study - Abstract
The effect of antibiotherapy on PSA levels and prostate biopsy results in patients with PSA levels 2.5-10 ng/mL - Abstract
Pathologic outcomes in men with low-risk and very low-risk prostate cancer: Implications on the practice of active surveillance - Abstract
Differences in self-reported outcomes of open prostatectomy patients and robotic prostatectomy patients in an international web-based survey - Abstract
Treatment for Localized Prostate Cancer

Advanced Prostate Cancer

ASCO 2013 - Slide Lecture: Prognosis and prediction of outcomes in castration-resistant prostate cancer
Johnson & Johnson announces definitive agreement to acquire Aragon Pharmaceuticals, Inc.
ASCO 2013 - Slide Lecture: Effect of corticosteroid use at baseline on overall survival in patients receiving abiraterone acetate: Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer post-docetaxel
Cabazitaxel in patients with metastatic castration-resistant prostate cancer: Results of a Compassionate Use Program in The Netherlands - Abstract
ASCO 2013 - Poster: A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: P
ASCO 2013 - Poster: Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
ASCO 2013 - Poster: A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer
ASCO 2013 - Poster: Randomized double-blind, comparative study of abiraterone acetate plus low-dose prednisone plus androgen deprivation therapy (ADT) vs ADT alone in newly diagnosed, high-risk, metastatic hormone-naïve prostate cancer
ASCO 2013 - Poster: Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases
ASCO 2013 - Poster: Hematologic safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial
ASCO 2013 - Poster: CA184-095: A randomized, double-blind, phase 3 trial to compare the efficacy of ipilimumab vs placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration-resistant prostate cancer
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy - Abstract
Phase I pharmacokinetic and biodistribution study with escalating doses of (223)Ra-dichloride in men with castration-resistant metastatic prostate cancer - Abstract
Unmet needs in the prediction and detection of metastases in prostate cancer - Abstract

Prostate Cancer Immunotherapy

A message to our readers:

During the past 10 years, UroToday has created – and continues to grow – a truly unique and comprehensive database of urologic content. While we pride ourselves in the ability to provide our readers with free access to over 60,000 pages of content, we now require that all guests be registered and logged on before proceeding to our online resources and archive.

We invite you to take a moment to register. After that, you may simply log on with your user name and password whenever you visit our site.

twitter     facebook     linkedin     youtube     email us
UroToday - 2217 Fifth Street - Berkeley, CA 94710 USA
Update Your Email Preferences   |   Unsubscribe   |   Forward this Email to a Friend
You are receiving this email because you have chosen to receive emails from UroToday.com. Log in to update your email address or view your email preferences. If you have any questions about your account, please log in to contact us securely and we will be happy to assist you.

click here to view this message online  

prostate<br />
cancer weekly header

Prostate Cancer

A discussion of the value and benefit of transrectal power Doppler sonography for detecting low-risk prostate cancers, "Beyond the Abstract," by J.-L. Sauvain, and E. Sauvain
Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease - Abstract
Racial differences in social support and coping among family caregivers of patients with prostate cancer - Abstract
Prostate cancer risk in rre-diabetic men: A matched cohort study - Abstract
High dose rate brachytherapy as monotherapy for localised prostate cancer: A hypofractionated two-implant approach in 351 consecutive patients - Abstract
Real-time contrast-enhanced transrectal US-guided prostate biopsy: Diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings - Abstract
Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population? - Abstract
Sentinel lymph node dissection in more than 1200 prostate cancer cases: Rate and prediction of lymph node involvement depending on preoperative tumor characteristics - Abstract
Application and clinical benefits of degarelix, a GnRH antagonist, in the treatment of advanced prostate cancer, "Beyond the Abstract," by Neal D. Shore, MD, FACS
Statement by NIH Director Francis Collins on U.S. Supreme Court ruling on gene patenting
Breaking News: Can someone else patent your genes? No, according to a closely watched ruling from the U.S. Supreme Court Thursday morning
ASCO 2013 - Poster: Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer
ASCO 2013 - Poster: A phase II multicenter study of the investigational single agent orteronel (TAK-700) in non-metastatic castration-resistant prostate cancer (nmCRPC [M0]) and rising prostate-specific antigen (PSA)
Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: Results from a randomized trial - Abstract
Sperm banking is of key importance in patients with prostate cancer - Abstract
Patients undergoing radical prostatectomy have a better survival than the background population - Abstract
Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer - Abstract
Classifying the reasons men consider to be important in prostate-specific antigen (PSA) testing decisions: Evaluating risks, lay beliefs, and informed decisions - Abstract
Plan of the day selection for online image-guided adaptive post-prostatectomy radiotherapy - Abstract
Current role of surgery for high risk prostate cancer - Abstract
Cost-benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer - Abstract
Platinum-based chemotherapy for variant castrate-resistant prostate cancer - Abstract
Functional and molecular imaging of localized and recurrent prostate cancer - Abstract
PSA screening and deaths from prostate cancer after diagnosis-A population based analysis - Abstract
Discussing uncertainty and risk in primary care: Recommendations of a multi-disciplinary panel regarding communication around prostate cancer screening - Abstract
Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer - Abstract
Pre-radiotherapy PSA level as a predictor for biochemical control in prostate cancer patients receiving radiotherapy after radical prostatectomy - Abstract
Assessment of antimicrobial prophylaxis to prevent perioperative infection in patients undergoing prostate brachytherapy: Multicenter cohort study - Abstract
Radiotherapy in the management of prostate cancer after radical prostatectomy - Abstract
Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes - Abstract
Prostate cancer detection by using digital rectal examination: Contemporary practice patterns in the United States - Abstract
Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy - Abstract
Management of high-risk prostate cancer: Radiation therapy and hormonal therapy - Abstract
Image-guided method for TLD-based in vivo rectal dose verification with endorectal balloon in proton therapy for prostate cancer - Abstract
Investigation of (90)Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I–II clinical study - Abstract
Bone turnover markers in patients with prostate carcinoma: Influence of sex steroids levels - Abstract
Anxiety status and its relationship with general health related quality of life among prostate cancer patients in two university hospitals in Kuala Lumpur, Malaysia - Abstract
Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study - Abstract
The effect of antibiotherapy on PSA levels and prostate biopsy results in patients with PSA levels 2.5-10 ng/mL - Abstract
Pathologic outcomes in men with low-risk and very low-risk prostate cancer: Implications on the practice of active surveillance - Abstract
Differences in self-reported outcomes of open prostatectomy patients and robotic prostatectomy patients in an international web-based survey - Abstract
Treatment for Localized Prostate Cancer

Advanced Prostate Cancer

ASCO 2013 - Slide Lecture: Prognosis and prediction of outcomes in castration-resistant prostate cancer
Johnson & Johnson announces definitive agreement to acquire Aragon Pharmaceuticals, Inc.
ASCO 2013 - Slide Lecture: Effect of corticosteroid use at baseline on overall survival in patients receiving abiraterone acetate: Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer post-docetaxel
Cabazitaxel in patients with metastatic castration-resistant prostate cancer: Results of a Compassionate Use Program in The Netherlands - Abstract
ASCO 2013 - Poster: A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: P
ASCO 2013 - Poster: Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
ASCO 2013 - Poster: A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer
ASCO 2013 - Poster: Randomized double-blind, comparative study of abiraterone acetate plus low-dose prednisone plus androgen deprivation therapy (ADT) vs ADT alone in newly diagnosed, high-risk, metastatic hormone-naïve prostate cancer
ASCO 2013 - Poster: Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases
ASCO 2013 - Poster: Hematologic safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial
ASCO 2013 - Poster: CA184-095: A randomized, double-blind, phase 3 trial to compare the efficacy of ipilimumab vs placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration-resistant prostate cancer
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy - Abstract
Phase I pharmacokinetic and biodistribution study with escalating doses of (223)Ra-dichloride in men with castration-resistant metastatic prostate cancer - Abstract
Unmet needs in the prediction and detection of metastases in prostate cancer - Abstract

Prostate Cancer Immunotherapy

A message to our readers:

During the past 10 years, UroToday has created – and continues to grow – a truly unique and comprehensive database of urologic content. While we pride ourselves in the ability to provide our readers with free access to over 60,000 pages of content, we now require that all guests be registered and logged on before proceeding to our online resources and archive.

We invite you to take a moment to register. After that, you may simply log on with your user name and password whenever you visit our site.

twitter     facebook     linkedin     youtube     email us
UroToday - 2217 Fifth Street - Berkeley, CA 94710 USA
Update Your Email Preferences   |   Unsubscribe   |   Forward this Email to a Friend
You are receiving this email because you have chosen to receive emails from UroToday.com. Log in to update your email address or view your email preferences. If you have any questions about your account, please log in to contact us securely and we will be happy to assist you.

Please let me know which of these studies you are interested in reading, and I will be happy to post the entere abstract, or you can register to the site, either one is fine with me...I am happy to post the abstracts for any studies that you select

 

click here to view this message online  

prostate<br />
cancer weekly header

Prostate Cancer

A discussion of the value and benefit of transrectal power Doppler sonography for detecting low-risk prostate cancers, "Beyond the Abstract," by J.-L. Sauvain, and E. Sauvain
Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease - Abstract
Racial differences in social support and coping among family caregivers of patients with prostate cancer - Abstract
Prostate cancer risk in rre-diabetic men: A matched cohort study - Abstract
High dose rate brachytherapy as monotherapy for localised prostate cancer: A hypofractionated two-implant approach in 351 consecutive patients - Abstract
Real-time contrast-enhanced transrectal US-guided prostate biopsy: Diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings - Abstract
Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population? - Abstract
Sentinel lymph node dissection in more than 1200 prostate cancer cases: Rate and prediction of lymph node involvement depending on preoperative tumor characteristics - Abstract
Application and clinical benefits of degarelix, a GnRH antagonist, in the treatment of advanced prostate cancer, "Beyond the Abstract," by Neal D. Shore, MD, FACS
Statement by NIH Director Francis Collins on U.S. Supreme Court ruling on gene patenting
Breaking News: Can someone else patent your genes? No, according to a closely watched ruling from the U.S. Supreme Court Thursday morning
ASCO 2013 - Poster: Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer
ASCO 2013 - Poster: A phase II multicenter study of the investigational single agent orteronel (TAK-700) in non-metastatic castration-resistant prostate cancer (nmCRPC [M0]) and rising prostate-specific antigen (PSA)
Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: Results from a randomized trial - Abstract
Sperm banking is of key importance in patients with prostate cancer - Abstract
Patients undergoing radical prostatectomy have a better survival than the background population - Abstract
Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer - Abstract
Classifying the reasons men consider to be important in prostate-specific antigen (PSA) testing decisions: Evaluating risks, lay beliefs, and informed decisions - Abstract
Plan of the day selection for online image-guided adaptive post-prostatectomy radiotherapy - Abstract
Current role of surgery for high risk prostate cancer - Abstract
Cost-benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer - Abstract
Platinum-based chemotherapy for variant castrate-resistant prostate cancer - Abstract
Functional and molecular imaging of localized and recurrent prostate cancer - Abstract
PSA screening and deaths from prostate cancer after diagnosis-A population based analysis - Abstract
Discussing uncertainty and risk in primary care: Recommendations of a multi-disciplinary panel regarding communication around prostate cancer screening - Abstract
Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer - Abstract
Pre-radiotherapy PSA level as a predictor for biochemical control in prostate cancer patients receiving radiotherapy after radical prostatectomy - Abstract
Assessment of antimicrobial prophylaxis to prevent perioperative infection in patients undergoing prostate brachytherapy: Multicenter cohort study - Abstract
Radiotherapy in the management of prostate cancer after radical prostatectomy - Abstract
Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes - Abstract
Prostate cancer detection by using digital rectal examination: Contemporary practice patterns in the United States - Abstract
Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy - Abstract
Management of high-risk prostate cancer: Radiation therapy and hormonal therapy - Abstract
Image-guided method for TLD-based in vivo rectal dose verification with endorectal balloon in proton therapy for prostate cancer - Abstract
Investigation of (90)Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I–II clinical study - Abstract
Bone turnover markers in patients with prostate carcinoma: Influence of sex steroids levels - Abstract
Anxiety status and its relationship with general health related quality of life among prostate cancer patients in two university hospitals in Kuala Lumpur, Malaysia - Abstract
Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study - Abstract
The effect of antibiotherapy on PSA levels and prostate biopsy results in patients with PSA levels 2.5-10 ng/mL - Abstract
Pathologic outcomes in men with low-risk and very low-risk prostate cancer: Implications on the practice of active surveillance - Abstract
Differences in self-reported outcomes of open prostatectomy patients and robotic prostatectomy patients in an international web-based survey - Abstract
Treatment for Localized Prostate Cancer

Advanced Prostate Cancer

ASCO 2013 - Slide Lecture: Prognosis and prediction of outcomes in castration-resistant prostate cancer
Johnson & Johnson announces definitive agreement to acquire Aragon Pharmaceuticals, Inc.
ASCO 2013 - Slide Lecture: Effect of corticosteroid use at baseline on overall survival in patients receiving abiraterone acetate: Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer post-docetaxel
Cabazitaxel in patients with metastatic castration-resistant prostate cancer: Results of a Compassionate Use Program in The Netherlands - Abstract
ASCO 2013 - Poster: A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: P
ASCO 2013 - Poster: Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
ASCO 2013 - Poster: A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer
ASCO 2013 - Poster: Randomized double-blind, comparative study of abiraterone acetate plus low-dose prednisone plus androgen deprivation therapy (ADT) vs ADT alone in newly diagnosed, high-risk, metastatic hormone-naïve prostate cancer
ASCO 2013 - Poster: Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases
ASCO 2013 - Poster: Hematologic safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial
ASCO 2013 - Poster: CA184-095: A randomized, double-blind, phase 3 trial to compare the efficacy of ipilimumab vs placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration-resistant prostate cancer
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy - Abstract
Phase I pharmacokinetic and biodistribution study with escalating doses of (223)Ra-dichloride in men with castration-resistant metastatic prostate cancer - Abstract
Unmet needs in the prediction and detection of metastases in prostate cancer - Abstract

Prostate Cancer Immunotherapy

A message to our readers:

During the past 10 years, UroToday has created – and continues to grow – a truly unique and comprehensive database of urologic content. While we pride ourselves in the ability to provide our readers with free access to over 60,000 pages of content, we now require that all guests be registered and logged on before proceeding to our online resources and archive.

We invite you to take a moment to register. After that, you may simply log on with your user name and password whenever you visit our site.

twitter     facebook     linkedin     youtube     email us
UroToday - 2217 Fifth Street - Berkeley, CA 94710 USA
Update Your Email Preferences   |   Unsubscribe   |   Forward this Email to a Friend
You are receiving this email because you have chosen to receive emails from UroToday.com. Log in to update your email address or view your email preferences. If you have any questions about your account, please log in to contact us securely and we will be happy to assist you.
Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2014 © Cancer Survivors Network